Quantcast

Latest Glycosides Stories

2010-05-21 07:35:00

QUEBEC CITY, May 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that data on two of its lead anticancer compounds, perifosine and AEZS-108, will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4 through 8, 2010 at McCormick Place in Chicago. Two posters on perifosine, Aeterna...

2010-05-18 00:30:00

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL). While CHOP-R is considered the standard of...

2010-05-13 00:30:00

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) (the "Company") today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. The trial will be conducted through the NCCTG, a national network of cancer specialists at community...

2010-05-12 06:30:00

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer. Following this...

2010-05-06 06:30:00

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in...

2010-04-26 07:00:00

OAK BROOK, Ill., April 26 /PRNewswire/ -- PureCircle, the world's leading producer and marketer of stevia-based, all-natural, zero-calorie sweeteners, and Michigan State University (MSU), one of the world's premier horticultural research institutions, have signed an agreement for research and breeding of the stevia plant. The agreement brings MSU's highly technical staff and resources of the Department of Horticulture to bear on stevia rebaudiana. The plant, native to Paraguay, has been...

2010-04-14 05:18:00

WAYZATA, Minnesota, April 14, 2010 /PRNewswire/ -- The European Food Safety Authority (EFSA) today published a Scientific Opinion, which confirms that steviol glycosides, sweeteners extracted from the stevia plant, are safe for use in foods and beverages and establishes an Acceptable Daily Intake (ADI) for their safe consumption. In its published Scientific Opinion, EFSA's Panel on Food Additives and Nutrient Sources Added to Foods (ANS) concludes that, considering the available...

2010-04-12 07:00:00

OAK BROOK, Ill., April 12 /PRNewswire-FirstCall/ -- PureCircle (The International Stock Exchange, London: PURE), the world's leading producer of naturally zero-calorie sweeteners , including stevia-derived Reb A, today announced that it will formally launch its effort to help reduce obesity in the United States by joining the Healthy Weight Commitment Foundation (HWCF). A first-of-its-kind endeavor, the HWCF involves the collaboration of more than 40 members of the food and beverage...

80387e1f6946cb36f02a09b3f3c355651
2010-03-29 10:30:00

An all-natural, herbal artificial sweetener, approved for use in the U.S. in December 2008, has already earned a market share of $500 million, according to a March 28 AFP report. Rebaudioside A (Reb-A) and Purevia are two products made from a South American herb known as stevia, and have become attractive alternatives to aspartame and other sugar-replacing artificial sweeteners because it is all natural. According to Mintel, a global marketing research firm originally founded in the United...

2010-03-18 06:30:00

COLUMBIA, Md., March 18 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with...


Latest Glycosides Reference Libraries

45_20138aaa34c0aef5a2af87b137102229
2009-04-23 11:07:34

Bittercress (Barbarea vulgaris), also commonly known as Herb Barbara, Rocketcress, Yellow Rocketcress, Winter Rocket, and Wound Rocket, is a European biennial herb. This plant displays a rosette of shiny, dark green leaves at the base and additional pinnately divided leaves on the stem. In the spring, yellow flowers originate in tightly packed terminal groups just above the foliage. Bittercress grows wildly as a weed in many parts of North America. The flowers can be in bloom May...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related